



Cerba Healthcare and VitaDX sign a partnership to validate the VisioCyt® test for the early diagnosis of bladder cancer

Issy Les Moulineaux and Rennes - France, 12 June 2017.

Cerba HealthCare (Issy Les Moulineaux - France) and VitaDX (Rennes - France) today announced the signing of a partnership to validate the VisioCyt® test.

VisioCyt® is an innovative and non-invasive method that improves the performance of urinary cytology, used as a first-line for the detection of cancers.

The analysis relies on algorithmic processing of images of urinary cytology scanned in transmission and fluorescence, prepared according to a specific and proprietary protocol.

The VisioCyt® solution will allow for metabolic evaluation by fluorescence coupled with an analysis of cell morphology in white light for the detection of tumor cells especially at an early stage of malignancy. The method developed is compatible with the equipment conventionally used by the anatomical pathology laboratories. The microscope slides produced are digitized and analyzed by the image processing software, based on Machine Learning algorithms.

VisioCyt® will position itself very early in the cancer diagnosis chain, before the deleterious effects of the pathology are present and will thus allow an improvement of the care of the patient.

The first step in this collaboration between VitaDX and Cerba HealthCare is to provide technical, scientific and medical support to VitaDX in order to refine the market access strategy and the commercial deployment of the first VitaDX product, VisioCyt®.

At the end of the clinical validation study and according to the performance of the test, Cerba HealthCare will benefit from an exclusivity to carry out the test developed by VitaDX, in 4 strategic geographical areas: France, Belgium, Luxembourg and United Arab Emirates.

"We are very pleased to announce this strategic partnership that demonstrates the potential of VisioCyt® to address the growing problem of bladder cancer," said Allan Rodriguez, CEO of VitaDX. The support of Cerba HealthCare represents a major asset for the success of our company. "

"This partnership with VitaDX is another example of our innovation strategy: early identification of promising tests and collaboration with innovative start-ups to accelerate our ability to offer useful tests to patients and healthcare professionals as soon as possible." Jérôme Sallette, Director of Innovation and Development at Cerba Healthcare

About Cerba HealthCare

The Group operates in three complementary segments:

- medical biology mainly in France, Belgium, Luxembourg, Italy and the United Arab Emirates with more than 300 laboratories, 150 sampling centers and 50 technical platforms;
- specialized medical biology through the Cerba Laboratory, a historical laboratory serving more than 50 countries in Europe, Africa and Asia;
- the biology of clinical trials, essential for the pharmaceutical and biotechnology industry in the development processes of new molecules, through its subsidiaries located on 5 continents.

Recently, the Group diversified into the veterinary biology market by creating Cerba Vet, a dedicated entity.

It employs nearly 4,300 employees, including more than 400 biologists. In 2016, its consolidated turnover is 640 million euros.

<http://www.cerbahealthcare.com>

About VitaDX

VitaDX International SA was founded in April 2015 on the basis of work carried out over the past 10 years within the Paris hospitals (Hôpitaux de l'Assistance Publique-Hôpitaux de Paris, AP-HP), the Paris-South University and the CNRS, with the objective of becoming a major player in the early diagnosis of cancer by exploiting fluorescence, image processing and artificial intelligence, more specifically deep learning. The company is supported by the SATT Paris-Saclay as part of a collaboration with the ONERA (French Aerospace Lab) for the development of the image processing algorithms.

2 years after its creation, the VitaDX team is made up of 14 people currently working on the development of the company, on the Rennes and Paris sites. On January 5, 2017, VitaDX launched its first clinical trial in partnership with several hospital centers of excellence. After a first € 1.2 million fundraising exercise in July 2015, VitaDX has completed a € 1.6 million fund raising on June 6, 2017 with GO CAPITAL, AURIGA Partners and individual investors.

www.vitadx.com

Press Contacts

Cerba HealthCare
Pascale Laurent
Communication and marketing Director
pascale.laurent@cerbahealthcare.com

VitaDX International
Allan Rodriguez
CEO
allan@vitadx.com